...
首页> 外文期刊>ORL: Journal for oto-rhino-laryngology and its borderlands >Role of Leukotriene Inhibitors in the Postoperative Management of Nasal Polyps.
【24h】

Role of Leukotriene Inhibitors in the Postoperative Management of Nasal Polyps.

机译:白三烯抑制剂在鼻息肉术后管理中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

This was a prospective double blind comparative study on 40 patients. It compared the effects of the leukotriene receptor antagonist montelukast and beclomethasone nasal spray on the post-operative course of patients with sinonasal polyps. All patients underwent endoscopic sphenoethmoidectomy and were randomized post-operatively into two groups. Group I: 20 patients (9 females and 11 males) age 17 to 67 (32.4 +/- 9.5 years), receiving 10 mg montelukast orally daily and Group II: 20 patients (6 females and 14 males) age 17 years to 57 years (33.5 +/- 11.9 years), receiving 400 ug beclomethasone local sprays daily. All patients were followed up for 1 year and a symptom score was recorded throughout this period. There was a significant reduction in symptom scores in both groups throughout the study period. In the montelukast group improvement was more marked in itching, post-nasal discharge and headache. The control of sneezing and rhinorrhea was comparable in both groups with a marginal advantage of montelukast. Steroids had a more marked effect on smell disturbances and obstruction. There was no difference in the recurrence rate or in the need for rescue medications between both groups. Both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment. Copyright (c) 2005 S. Karger AG, Basel.
机译:这是一项针对40例患者的前瞻性双盲比较研究。它比较了白三烯受体拮抗剂孟鲁司特和倍氯米松鼻喷雾剂对鼻窦息肉患者术后的影响。所有患者均接受内镜蝶窦切除术,术后随机分为两组。第一组:20例患者(9名女性和11名男性),年龄17至67岁(32.4 +/- 9.5岁),每天口服孟鲁司特10 mg;第二组:20例患者(6名女性和14名男性),年龄17岁至57岁(33.5 +/- 11.9岁),每天接受400克倍氯米松局部喷雾剂。所有患者均接受了为期一年的随访,并在此期间记录了症状评分。在整个研究期间,两组的症状评分均显着降低。孟鲁司特组在瘙痒,流鼻涕和头痛方面的改善更为明显。两组的打喷嚏和流鼻涕的控制相当,孟鲁司特的优势很小。类固醇对气味干扰和阻塞有更明显的作用。两组之间的复发率或急救药物的需求没有差异。两种药物似乎具有互补作用,需要进一步研究以确定哪些患者应接受哪种治疗。版权所有(c)2005 S.Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号